New Medications and Prescribing Methods for Diabetic Patients

Transcription

1 New Medications and Prescribing Methods for Diabetic Patients Jeffrey Stroup, PharmD, BCPS, FCCP Professor of Medicine Oklahoma State University Center for Health Sciences Department of Internal Medicine

2 Disclosure I have no relevant financial relationships or affiliations with commercial interests to disclose

3 Objectives Identify the sites of action of each of the diabetes treatments Identify contraindications and side effects of each diabetes treatment Differentiate the HbA1C reduction among each of the diabetes treatments Identify and differentiate between diabetes treatments that can cause weight gain or weight loss Identify preferred antihypertensive agents utilized in patients with diabetes Identify preferred lipid agents utilized in patients with diabetes

4 Guidelines-Goals Variable ADA Recommendations Hb A1C * <7.0% (AACE < 6.5%) Preprandial Postprandial LDL* Triglycerides HDL Non-HDL Blood Pressure* mg/dL (AACE <110mg/dL) <180mg/dL (AACE < 140mg/dL) <100mg/dL (<70mg/dL with CVD hx) <150mg/dL >40mg/dL (women > 50mg/dL) <130mg/dL (If TG > 200mg/dL) <140/90 mmhg (<130/80 in some) Al/Cr <30 Other Aspirin, Pneumococcal and Influenza vaccines Diabetes Care. 2018; 41.

5 Approach to the Management of Hyperglycemia Patient/Disease Features Risk of hypoglycemia/drug adverse effects Disease Duration Life expectancy Important comorbidities Established vascular complications more stringent low newly diagnosed long absent absent A1C 7% Few/mild Few/mild less stringent high long-standing short severe severe Patient attitude & expected treatment efforts Resources & support system highly motivated, adherent, excellent self-care capabilities readily available less motivated, nonadherent, poor self-care capabilities limited Glycemic Targets: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S55-S64

6

7 Diabetes Education - Intensive Course for 2-4 weeks with certified diabetic educator - Follow-up every 3 months, more frequent as needed Survival Skills Insulin-preparation and injection Glucometer use and calibration, keeping logs Urine/serum ketone testing Glucagon emergency kit Nutrition Lifestyle Management: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S38-S50

8 Lifestyle Intervention (From the Diabetes Prevention Program) An intensive program with the following specific goals: > 7% loss of body weight and maintenance of weight loss Dietary fat goal: < 25% of calories from fat Calorie intake goal: kcal/day > 150 minutes per week of physical activity The DPP Research Group, NEJM 346: , 2002

9

10 Sulfonylureas Sulfonylureas increase endogenous insulin secretion Sulfonylureas stimulate insulin release by binding to a specific site on the β cell K ATP channel complex (SUR) and inhibiting its activity. K ATP channel inhibition causes cell membrane depolarization and the cascade of events leading to insulin secretion Efficacy Decrease fasting plasma glucose mg/dl Reduce A1C by % Other Effects Hypoglycemia Weight gain* No specific effect on plasma lipids or blood pressure Generally the least expensive class of medication Medications in this Class: First generation sulfonylureas: chlorpropamide (Diabinese) tolazamide acetohexamide (Dymelor) tolbutamide Second generation sulfonylureas: glyburide (Micronase, Glynase, and DiaBeta) glimepiride (Amaryl) glipizide (Glucotrol, Glucotrol XL) Chan JL, Abrahamson MJ. Mayo Clin Proc 2003; 78:

11 Biguanides Biguanides decrease hepatic glucose production and increase insulinmediated peripheral glucose uptake. Metformin has specific actions on mitochondrial respiration that reduce intracellular ATP and increase AMP. Efficacy Decrease fasting plasma glucose mg/dl Reduce A1C % Other Effects Diarrhea and abdominal discomfort Lactic acidosis if improperly prescribed Cause small decrease in LDL cholesterol level and triglycerides No specific effect on blood pressure No weight gain, with possible modest weight loss B12 deficiency reported Contraindicated in patients with an egfr below 30 ml/minute/1.73 m 2.* Starting metformin in patients with an egfr between ml/minute/1.73 m 2 is not recommended. Medications in this Class: metformin (Glucophage) metformin hydrochloride extended release (Glucophage XR) Chan JL, Abrahamson MJ. Mayo Clin Proc 2003; 78:

12 Thiazolidinediones Thiazolidinediones decrease insulin resistance by making muscle and adipose cells more sensitive to insulin. They also suppress hepatic glucose production. Thiazolidinediones are ligands for the PPARγ receptor, a nuclear hormone receptor that has two isoforms and is involved in the regulation of genes related to glucose and lipid metabolism. Efficacy Decrease fasting plasma glucose ~50-80 mg/dl Reduce A1C ~ % 6 weeks for maximum effect Other Effects Weight gain, edema Contraindicated in patients with abnormal liver function or CHF (Class 3-4) Improves HDL cholesterol and plasma triglycerides; usually LDL neutral Medications in this Class: pioglitazone (Actos) bladder cancer warning rosiglitazone (Avandia) cardiovascular disease warning troglitazone (Rezulin) - taken off market due to liver toxicity Chan JL, Abrahamson MJ. Mayo Clin Proc 2003; 78:

13 Meglitinides Meglitinides stimulate insulin secretion (rapidly and for a short duration) in the presence of glucose. Like sulfonylureas, stimulate insulin release by closing K ATP channels in pancreatic β cells Efficacy Decreases peak postprandial glucose Decreases plasma glucose mg/dl ( mmol/l) Reduce A1C % Other Effects Hypoglycemia (although may be less than with sulfonylureas if patient has a variable eating schedule) Weight gain No significant effect on plasma lipid levels Safe at higher levels of serum Cr than sulfonylureas Medications in this Class: repaglinide (Prandin) nateglinide (Starlix) Chan JL, Abrahamson MJ. Mayo Clin Proc 2003; 78:

14 Alpha-glucosidase Inhibitors Alpha-glucosidase inhibitors block the enzymes that digest starches in the small intestine α-glucosidase inhibitors reduce intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α-glucosidase in the intestinal brush border Efficacy Decrease peak postprandial glucose mg/dl Decrease fasting plasma glucose (no sig effect) Decrease A1C % Other Effects Flatulence or abdominal discomfort No specific effect on lipids or blood pressure No weight gain Contraindicated in patients with inflammatory bowel disease or cirrhosis Medications in this Class: acarbose (Precose) miglitol (Glyset) Chan JL, Abrahamson MJ. Mayo Clin Proc 2003; 78:

15 Effects of Glucagon-like peptide-1 Idris I and Donnelly R. Diabetes Obes Metab. 2007;9:

16 Incretin Mimetics Efficacy Hemoglobin A1c lowering of 0.8% 1.9% Primarily a postprandial glucose reduction with exenatide BID Less postprandial and greater fasting glucose reduction with liraglutide and weekly products Dose Exenatide (Byetta): 5 mcg subcutaneously 2 times/day (thigh, abdomen, or upper arm) 1 60 minutes before morning and evening meals, increase to 10 mcg 2 times/ day after 4 weeks if tolerated Liraglutide (Victoza): 0.6 mg subcutaneously every day (independent of meals; inject into thigh, abdomen, or upper arm); increase by weekly intervals to 1.2 mg subcutaneously every day; then 1.8 mg subcutaneously every day if needed

17 Dose Incretin Mimetics Exenatide LAR (Bydureon): 2 mg subcutaneously weekly (thigh, abdomen, or upper arm); two weeks before see effect (6-8 weeks full effect) Albiglutide (Tanzeum): 30 mg subcutaneously weekly (independent of meals; inject into thigh, abdomen, or upper arm); can increase to 50 mg after 4 weeks if needed. Dulaglutide (Trulicity): 0.75 mg subcutaneously weekly (independent of meals; inject into thigh, abdomen, or upper arm); can increase to 1.5 mg after 4 weeks if needed.

18 Incretin Mimetics Adverse Effects GI: Nausea, Vomiting, Diarrhea Headache Rare: Pancreatitis/Renal dysfunction Contraindications Gastroparesis Creatinine clearance < 30 ml/minute: Exenatide and Exenatide LAR Medullary thyroid carcinoma (MTC), personal or family history, or in patients with multiple endocrine neoplasia syndrome type 2 (MEN2): Liraglutide and Weekly products Pancreatitis

19 Incretin Mimetics Advantages Use is associated with weight loss (2-3 kg) Convenient dosing B-cell sparing effect? Disadvantages Parenteral administration Gastrointestinal adverse effects May reduce the rate and extent of absorption of drugs that require rapid absorption (pain relievers, antibiotics, and oral contraceptives); separate administration by at least 1 hour Cost

20 GLP-1 Comparison Chart Drug Byetta Bydureon Tanzeum Trulicity Victoza Generic exenatide exenatide albiglutide dulaglutide liraglutide Dosing Frequency Dosing Mixing Required Waiting Time post mixing Twice daily 5 mcg 10 mcg Weekly Weekly Weekly Daily 2 mg 30 mg 50 mg 0.75 mg 1.5 mg No Yes Yes No No None None 15 or 30 minutes None 0.6 mg 1.2 mg 1.8 mg None Needle Size 32 g; 4mm 23 g; 8 mm 29 g; 5 mm 29 g;built-in 32 g; 4 mm Auto-injector No No No Yes No Use with basal insulin Yes No Yes No Yes

21 GLP-1=glucagon-like peptide-1; GIP=glucose-dependent insulinotropic polypeptide. Mechanism of Action of DPP-IV Inhibitors GI tract Ingestion of food Release of active incretins GLP-1 and GIP DPP-4 inhibitor Inactive GLP-1 X DPP-4 enzyme Inactive GIP Pancreas Beta cells Alpha cells Glucosedependent Glucose dependent Insulin (GLP-1and GIP) Glucagon (GLP-1) Glucose uptake by peripheral tissue Hepatic glucose production Blood glucose in fasting and postprandial states Incretin hormones GLP-1 and GIP are released by the intestine throughout the day, and their levels in response to a meal.

22 Pharmacology JANUVIA (SITAGLIPTIN) ONGLYZA (SAXAGLIPTIN) TRADJENTA (LINAGLIPTIN) NESINA (ALOGLIPTIN) Dosing Frequency Dosage 25, 50, 100 mg 2.5 & 5 mg 5 mg 6.25, 12.5, 25 mg Half-life (hours) (active metabolite= 3.1) Metabolism Not extensively metabolized CYP3A4/5 > (active metabolite) Not extensively metabolized CYP2D6/3A4 Majority of Elimination Dose Adjustment in CKD/ESRD Renal Renal Bile Renal -- Combination Products

23 DPP-IV Inhibitors Good vs. Bad Low risk of hypoglycemia Weight neutral Once daily ORAL Well tolerated URI Nasal pharyngitis Headache Hypersensitivity Pancreatitis

24 Incretin Comparison GLP-1 Activation DPP-IV Inhibition Insulin Glucagon Gastric emptying Hypoglycemia +/- -- Nausea/Vomiting Weight Loss No Change Route of admin Injection Oral

25 Other Available Agents Pramlintide (Symlin ) Used in type 1 and type 2 diabetes Amylin analog (hormone co-secreted with insulin) Injectable three times daily Weight loss Colesevelam (Welchol ) Lipid agent Used in type 2 diabetes A1c reduction ~0.5% Bromocriptine (Cycloset ) Dopamine receptor agonist Used in type 2 diabetes A1c reduction ~0.5%

26 Sodium- Glucose Cotransporters Site SGLT1 Mostly intestine with some kidney SGLT2 Sugar Specificity Glucose or galactose Glucose Affinity for glucose Capacity for glucose transport Role High Km= 0.4 Mm Low Dietary glucose absorption Renal glucose reabsorption Almost exclusively kidney Low Km = 2 Mm High Renal glucose reabsorption Lee YJ, at al. Kidney Int Suppl. 2007;72:S27-S35.

27 Targeting the Kidney Chao EC, et al. Nat Rev Drug Discovery. 2010;9:

28 Effects of SGLT2 Inhibitors Inhibition of renal tubular Na + - glucose cotransporter reversal of hyperglycemia reversal of glucotoxicity Insulin sensitivity in muscle GLUT4 translocation Insulin signaling Insulin sensitivity in liver Glucose-6-phosphatase Gluconeogenesis Decreased Cori Cycle PEP carboxykinase Improved beta cell function DeFronzo RA, et al. Diabetes Obes Metab. 2012;14(1):5-14.

29 Sodium-Glucose co-transporter 2 Inhibitors. Mechanism of Action Blocks SGLT-2 receptors in the proximal tubule thus inhibiting renal reabsorption of glucose. This results in glycosuria, as well as salt and water loss. Efficacy Hemoglobin A1c lowering of 0.7% 1.1%. Lowers fasting and postprandial glucose levels Weight loss BP reduction Dose Canagliflozin (Invokana): 100 mg once daily; may increase to 300 mg Dapagliflozin (Farxiga): 5 mg once daily; may increase to 10 mg Empagliflozin (Jardiance): 10 mg daily once daily; may increase to 25 mg

30 Dose Adjustments for Renal Insufficiency egfr (ml/min/1.73m 2) Canagliflozin (Invokana) Dapagliflozin (Farxiga) Empagliflozin (Jardiance) > 60 No dosage adjustment No dosage adjustment No dosage adjustment mg daily Not recommended for egfr <60 No dosage adjustment < 45 Not recommended Not recommended Not recommended INVOKANA [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; FARXIGA [prescribing information]. Bristol-Myers Squibb & AstraZeneca Pharmaceuticals, Inc.; JARDIANCE [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc. & Eli Lilly and Company; 2014.

31

32 SGLT-2 Inhibitors Adverse Effects Genital mycotic infections Women: % (SGLT2) vs % (placebo) Men (more common if uncircumcised): % (SGLT2) vs % (placebo) Urinary tract infections % (SGLT2) vs % (placebo) Polyuria Risk of hypotension and hypovolemia due to osmotic diuresis Euglycemic ketoacidosis (EKA, eudka) Invokana PI; Farxiga PI; Jardiance PI

33 SGLT-2 Inhibitor Summary Advantages Once daily oral administration Effect independent of insulin secretion or insulin resistance Low risk of hypoglycemia Decreases both FBG and PPG Weight Loss (2-3kg) Blood pressure lowering (~5 mmhg SBP) Concerns Polyuria (additional ml/day) Dehydration Hypotension Genital mycotic infection Urinary tract infection

34 The History of Insulins 1889: Pancreas & DM 1951: Lente insulins 1921: Extraction of insulin 1970 s: Single source insulins 1980 s: Premixed insulin. 1922: 1st successful use Human insulin of insulin 1990 s: Insulin Analogs s: Joslin advocates (Quick-acting insulin). tight glycemic control DCCT/UKPDS 1936: PZI insulin 2000: Basal Insulin. DCCT/EDIC 1946: NPH insulin 2006: Inhaled Insulin

35 Insulin Therapy in Type 2 Diabetes Arguments for Earlier Use

36 Insulin analogues. Modifications of native insulin can alter its pharmacokinetic profile. Reversing amino acids 28 and 29 in the B chain (lispro) or substituting Asp for Pro 28B (aspart) gives analogues with reduced tendencies for molecular self-association that are faster acting. Altering Asp 3B to Lys and Lys 29B to Glu produces an insulin (glulisine) with a more rapid onset and a shorter duration of action. Substituting Gly for Asn 21A and lengthening the B chain by adding Arg 31 and Arg 32 produces a derivative (glargine) with reduced solubility at ph 7.4 that is, consequently, absorbed more slowly and acts over a longer period of time. Deleting Thr 30B and adding a myristoyl group to the ε-amino group of Lys 29B (detemir) enhances reversible binding to albumin, thereby slowing transport across vascular endothelium to tissues and providing prolonged action. Insulin degludec is LysB29(Nεhexadecandioyl-γ-Glu) des(b30) human insulin. When degludec is injected subcutaneously, it forms multihexameric complexes that slow absorption; degludec also binds well to albumin; these two characteristics contribute to the prolonged effect of degludec (>24 h at steady state).

37 Comparison of Human Insulins Insulin Onset Peak Duration Lispro, Aspart, Glulisine 5-15 mins 1-2 hrs 3-5 hrs Inhaled Insulin Minutes min 2-3 hrs Human Regular mins 2-4 hrs 6-8 hrs Human NPH 1-2 hrs 6-12 hrs hrs Insulin Detemir 3-4 hrs Peakless hrs Insulin Glargine 4-6 hrs Peakless ~24 hrs Glargine U300 6 hrs Peakless ~30-36 hrs Insulin Degludec 6 hrs Peakless ~42 hrs

38 Profiles Human Insulin and Analogs Aspart, Lispro, Glulisine Regular Plasma insulin levels NPH Detemir Glargine Rosenstock J. Clin Cornerstone. 2001;4:50. Hours

39 Mimicking Nature Breakfast Lunch Dinner Insulin Action 4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00 Time Adapted with permission from Leahy J. In: Leahy J, Cefalu W, eds. Insulin Therapy. New York: Marcel Dekker; 2002:87; Nathan DM. N Engl J Med. 2002;347:1342

40 Evening Basal Insulin Bedtime NPH µu/ml B L D Normal pattern NPH Time of day B=breakfast; L=lunch; D=dinner

41 Split-Mixed Regimen Human Insulins µu/ml NPH Regular B L D NPH Regular Normal pattern Time of day B=breakfast; L=lunch; D=dinner

42 Multiple Daily Injections Human Insulins µu/ml NPH Regular Regular Regular NPH B L D Normal pattern B=breakfast; L=lunch; D=dinner Time of day

43 Basal-Bolus Insulin Treatment With Insulin Analogues µu/ml Lispro, glulisine, or aspart B L D Glargine qd or Detemir qd or bid Normal pattern Time of day B=breakfast; L=lunch; D=dinner

44 How To Initiate Insulin Therapy? Type 1 Patients Utilize a Basal/Bolus Approach Target Fasting & Postprandial Blood Sugars Type 2 Patients Failing Oral Therapy 1 st Target Fasting Blood Sugar Forced Titration Schedule

45 Initiating Insulin Therapy Empiric Dosing (daily dose) Insulin Analogues Type 1: 0.5 units/kg/d Type 2: units/kg/d (obesity, activities) Give 50% as Basal Insulin Give 50% as Bolus Insulin Split into three doses Adjust accordingly: Carbohydrate Counting

46 Initiating Basal Insulin Therapy Suppresses glucose production between meals and overnight Continue oral agent(s) at same dosage (may eventually reduce) Add single bedtime insulin dose (10 20 Units) [weight based at 0.2U/kg] Glargine Detemir NPH Adjust dose according to Fasting Blood Sugars Adjust the insulin dose every 3-4 days as needed Increase 2 U if FBG mg/dl Increase 4 U if FBG mg/dl Increase 6 U if FBG mg/dl Increase 8 U if FBG >180 mg/dl Treat to target (usually FPG mg/dl)

47 Riddle MC et al. Diabetes Care. 2003;26: Rosenstock J et al. Diabetologia. 2008;51: Treat to Target

48 Prandial Insulin Dose Adjustments Prandial insulin limits hyperglycemia after meals Set dose with meals Example dosing: 2-5 units with each meal to start Carbohydrate counting Typical start: 1 unit for every 10-15g of carbohydrate Correction scales

49 Initiating Pre-Meal Dosing Discontinue SFU or Meglitinide Initiate with the largest meal Once at goal, move to the next largest meal Diabetes Obes Metab. 2008; 10:

50 Humulin 70/30 70% NPH, 30% Regular Humulin 50/50 50% NPH, 50% Regular Humalog Mix 75/25 Mixed Insulins 75% lispro protamine, 25% lispro Humalog Mix 50/50 50% lispro protamine, 50% lispro Novolin 70/30 70% NPH, 30% Regular Novolog Mix 70/30 70% aspart protamine, 30% aspart

51 Respiratory Tract Surface Area - Total surface area of lungs = 140m 2 - Alveoli = regulation tennis court - Bronchi= blue towel

52 Insulin Human Inhalation Powder Inhaled, ultra-rapid-acting mealtime insulin Indicated for adults with T1DM or T2DM Administer at beginning of each meal 4 (blue), 8 (green), and 12 (yellow) unit packets Foil package; 2 blister cards, 15 cartridges each; strips of three; 2 inhalers. Dosing Insulin-naive patients: 4 units before each meal Prandial SC insulin users: convert 1:1 (round up to nearest 4 units) Afrezza Prescribing Information. October 2014.

53

54 Treatment Guideline Algorithms American Diabetes Association American Association of Clinical Endocrinologists*

55

56

57

58

59

60 Which of the following drugs used in treatment of Type 2 DM is consistently associated with weight loss? 1. Sulfonylureas 2. Thiazolidinediones 3. Glucagon-like peptide 1 analogs 4. Insulin

61 Which of the following treatments for Type 2 DM is associated with the most profound reduction in HbA1c? 1. Metformin 2. Insulin 3. Sulfonylureas 4. Thiazolidinediones

62 Which of the following agents is contraindicated with Class 3 or 4 Heart Failure? 1. Thiazolidinediones 2. Insulin 3. Sulfonylureas 4. Bromocriptine

63 Which of the following classes of diabetes medications works primarily at the level of the kidney? 1. DPP-IV inhibitors 2. Sulfonylureas 3. Insulin 4. SGLT-2 inhibitors

64 ADA Recommendations-HTN

65 ADA Recommendations-Statins

66 High- and Moderate-Intensity Statin Therapy Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S86-S104

67

68 Which of the following agents is preferred as an antihypertensive in patients with diabetes? 1. Beta blockers 2. ACE Inhibitors 3. Loop Diuretics 4. Hydralazine

69 QUESTIONS